Literature DB >> 24117478

The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance.

Won Sang Yoo1, Hoon Sung Choi, Sun Wook Cho, Jae Hoon Moon, Kyung Won Kim, Hyo Jin Park, So Yeon Park, Sang Il Choi, Sung Hee Choi, Soo Lim, Ka Hee Yi, Do Joon Park, Hak Chul Jang, Young Joo Park.   

Abstract

BACKGROUND: Atypia or follicular lesions of undetermined significance (AUS/FLUS) is a broad cytological category in the Bethesda system for classifying thyroid cytology. This study investigated the diagnostic accuracy of ultrasound (US) analysis of thyroid nodules with AUS/FLUS. PATIENTS AND METHODS: Of 5062 subjects with nodules subjected to fine-needle aspiration cytology (FNACs) at our institution from January 2010 through May 2012, 383 met the Bethesda criteria for AUS/FLUS. After excluding subjects who had a history of thyroid cancer, who only underwent repeat FNA or who underwent no further examinations, we selected 249 subjects who had subsequently undergone a core-needle biopsy and/or surgery. Of these, 100 were found to have malignant nodules (40·2%), 122 had benign nodules (49%), and 27 had nodules with indeterminate status (10·8%). We compared specific US parameters, including size, location, content, shape, margin, echogenicity, echotexture and calcification across these subject groups.
RESULTS: Multivariate analysis revealed that malignancy was associated with taller-than-wide shape (TDW) (OR = 8·43, P = 0·002), ill-defined margin (OR = 3·23, P = 0·002) and marked hypoechogenicity. (OR = 3·61, P = 0·001). The specificity and positive predictive values of TDW were 98% and 90·6%,respectively. The specificity and positive predictive values of 'TDW and marked hypoechogenicity' were both 100%.
CONCLUSION: US findings play a complementary role in the diagnosis of thyroid nodules with AUS/FLUS. In case of highly suspicious US findings such as 'TDW and marked hypoechogenicity', could be very helpful in the diagnosis of malignancy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24117478     DOI: 10.1111/cen.12348

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  29 in total

1.  The role of core needle biopsy in the diagnosis of initially detected thyroid nodules: a systematic review and meta-analysis.

Authors:  Sae Rom Chung; Chong Hyun Suh; Jung Hwan Baek; Young Jun Choi; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2018-05-22       Impact factor: 5.315

Review 2.  The role of core-needle biopsy in the diagnosis of thyroid malignancy in 4580 patients with 4746 thyroid nodules: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Jung Hwan Baek; Jeong Hyun Lee; Young Jun Choi; Kyung Won Kim; Jayoun Lee; Ki-Wook Chung; Young Kee Shong
Journal:  Endocrine       Date:  2016-05-25       Impact factor: 3.633

3.  Malignancy risk and characteristics of thyroid nodules with two consecutive results of atypia of undetermined significance or follicular lesion of undetermined significance on cytology.

Authors:  Vivian Youngjean Park; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon; Hee Jung Moon
Journal:  Eur Radiol       Date:  2015-03-05       Impact factor: 5.315

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  The Bethesda system for reporting thyroid cytopathology: a single-center experience over 5 years.

Authors:  Colleen M Kiernan; J T Broome; C C Solórzano
Journal:  Ann Surg Oncol       Date:  2014-05-06       Impact factor: 5.344

6.  Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology.

Authors:  Oya Topaloglu; Husniye Baser; Fatma Neslihan Cuhaci; Nuran Sungu; Abdussamed Yalcin; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2016-05-12       Impact factor: 3.633

7.  Repeat fine-needle aspiration can be performed at 6 months or more after initial atypia of undetermined significance or follicular lesion of undetermined significance results for thyroid nodules 10 mm or larger.

Authors:  Jieun Koh; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon; Hee Jung Moon
Journal:  Eur Radiol       Date:  2016-03-10       Impact factor: 5.315

8.  Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.

Authors:  Martina Rossi; Sabrina Lupo; Roberta Rossi; Paola Franceschetti; Giorgio Trasforini; Stefania Bruni; Federico Tagliati; Mattia Buratto; Giovanni Lanza; Luca Damiani; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2016-09-13       Impact factor: 3.633

9.  Outcome of Subclassification of Indeterminate (Thy-3) Thyroid Cytology into Thy-3a and Thy-3f.

Authors:  Catherine Brophy; Rania Mehanna; Julie McCarthy; Antoinette Tuthill; Matthew S Murphy; Patrick Sheahan
Journal:  Eur Thyroid J       Date:  2015-10-27

10.  Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?

Authors:  James J Figge; William E Gooding; David L Steward; Linwah Yip; Rebecca S Sippel; Samantha Peiling Yang; Randall P Scheri; Jennifer A Sipos; Susan J Mandel; Sarah E Mayson; Kenneth D Burman; Jessica M Folek; Bryan R Haugen; Julie A Sosa; Rajeev Parameswaran; Wee Boon Tan; Yuri E Nikiforov; Sally E Carty
Journal:  Thyroid       Date:  2021-09-01       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.